[Discussion] the telehealth advice in here is 3 years out of date
the telehealth advice in here is 3 years out of date, and I am aware this is a minority view on this board.
3 years. Those are measured, not estimated, and not rounded up in my favour.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Was there potency testing on the finished preparation, or only on the starting material?
ask what the beyond-use date is based on
ask what the beyond-use date is based on
This is the distinction the whole board runs on. Everything else follows from it.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
the pharmacy and the prescriber are two separate questions
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
ask which facility, then ask for their testing
the label on a compounded vial is a legal document, read it
the shortage list is the whole legal hinge and people skip it
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
- 1A beyond-use date derived from published stability data means something…6 comments in this branch · started by u/rina_sobczak